Premium
Lipid profile and thyroid hormone concentrations in children with epilepsy treated with oxcarbazepine monotherapy: a prospective long‐term study
Author(s) -
Garoufi A.,
Koemtzidou E.,
Katsarou E.,
Dinopoulos A.,
Kalimeraki I.,
Fotinou A.,
Drakatos A.,
Attilakos A.
Publication year - 2014
Publication title -
european journal of neurology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.881
H-Index - 124
eISSN - 1468-1331
pISSN - 1351-5101
DOI - 10.1111/ene.12262
Subject(s) - medicine , endocrinology , oxcarbazepine , thyroid , triiodothyronine , hormone , cholesterol , prospective cohort study , gastroenterology , epilepsy , carbamazepine , psychiatry
Background and purpose To evaluate prospectively the changes and possible associations in lipid and thyroid profiles in children treated with oxcarbazepine ( OXC ) monotherapy. Methods Serum total cholesterol ( TC ), high‐density lipoprotein cholesterol ( HDL ‐C), low‐density lipoprotein cholesterol ( LDL ‐C), triglycerides ( TG s), lipoprotein (a) [Lp(a)], free thyroxine ( FT 4), free triiodothyronine ( FT 3), thyrotropin ( TSH ) and gamma‐glutamyltransferase ( GGT ) concentrations were measured in 23 children with epilepsy, before and at 8 and 18 months of OXC monotherapy. Results Total cholesterol was significantly increased at 8 months ( P = 0.033), whereas LDL ‐C was significantly increased at 8 and 18 months ( P < 0.001 and P = 0.004, respectively) of treatment. Lp(a) was significantly increased at 8 months ( P = 0.042) and borderline significantly increased at 18 months ( P = 0.050) of treatment. FT 4 was significantly decreased at 8 and 18 months ( P < 0.001 and P = 0.002, respectively), and TSH levels were significantly increased at 8 and 18 months ( P = 0.002 and P = 0.001, respectively) of OXC monotherapy. GGT levels were significantly increased at 8 and 18 months ( P < 0.001) of treatment. There were no significant alterations in HDL ‐C, TG s and FT 3 levels during the study. Significant positive correlations were found between GGT and LDL ‐C levels at 8 ( r = 0.468, P = 0.024) and 18 months ( r = 0.498, P = 0.016), and between TSH and TC at 18 months ( r = 0.508, P = 0.013) of treatment. Conclusions OXC monotherapy may cause significant and persistent alterations in lipid and thyroid profiles in children with epilepsy. The increase in LDL ‐C and TC levels may be associated with liver enzymes induction and thyroid dysfunction. Further long‐term prospective studies are required to confirm these findings and to determine their clinical significance.